Comparison 7. Carbapenems versus other regimens.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality (all causes)	5	494	Odds Ratio (M‐H, Random, 95% CI)	1.35 [0.40, 4.56]
2 Mortality (all causes ‐ITT analysis)	5	1496	Odds Ratio (M‐H, Random, 95% CI)	1.04 [0.62, 1.76]
3 Mortality (due to infection)	6	852	Odds Ratio (M‐H, Random, 95% CI)	0.78 [0.30, 2.03]
4 Mortality (due to infection ‐ ITT analysis)	2	623	Odds Ratio (M‐H, Random, 95% CI)	0.75 [0.11, 5.03]
5 Clinical success	13	1720	Odds Ratio (M‐H, Random, 95% CI)	1.15 [0.78, 1.70]
5.1 Overall	12	1591	Odds Ratio (M‐H, Random, 95% CI)	1.15 [0.76, 1.75]
5.2 Appendix	1	129	Odds Ratio (M‐H, Random, 95% CI)	1.16 [0.34, 4.01]
6 Clinical success (ITT analysis)	4	1384	Odds Ratio (M‐H, Random, 95% CI)	0.71 [0.47, 1.07]
7 Microbiological success	3	164	Odds Ratio (M‐H, Random, 95% CI)	1.10 [0.15, 8.19]
8 Microbiological success (ITT analysis)	2	654	Odds Ratio (M‐H, Random, 95% CI)	0.78 [0.49, 1.24]
9 Wound infection	4	528	Odds Ratio (M‐H, Random, 95% CI)	0.73 [0.36, 1.49]
10 Intra‐abdominal abscess	4	644	Odds Ratio (M‐H, Random, 95% CI)	1.15 [0.61, 2.18]
11 Clinical sepsis	3	551	Odds Ratio (M‐H, Random, 95% CI)	0.97 [0.31, 3.01]
12 Remote infection	2	123	Odds Ratio (M‐H, Random, 95% CI)	2.15 [0.61, 7.56]
13 Superinfection	4	278	Odds Ratio (M‐H, Random, 95% CI)	1.01 [0.28, 3.64]
14 Adverse reactions	1	43	Odds Ratio (M‐H, Random, 95% CI)	1.28 [0.07, 21.86]
14.1 Overall	1	43	Odds Ratio (M‐H, Random, 95% CI)	1.28 [0.07, 21.86]
15 Adverse reactions (ITT analysis)	5	1396	Odds Ratio (M‐H, Random, 95% CI)	0.83 [0.63, 1.10]
15.1 Overall	4	881	Odds Ratio (M‐H, Random, 95% CI)	0.75 [0.55, 1.02]
15.2 Major	1	515	Odds Ratio (M‐H, Random, 95% CI)	1.33 [0.68, 2.62]
16 Duration of therapy	2	288	Mean Difference (IV, Random, 95% CI)	‐0.49 [‐1.96, 0.98]
17 Days hospitalised	1	129	Mean Difference (IV, Random, 95% CI)	‐1.40 [‐2.47, ‐0.33]
18 TIme to defervescence	1	129	Mean Difference (IV, Random, 95% CI)	‐1.30 [‐1.98, ‐0.62]